Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 0.40 |
| ▸ | CDK1 | P06493 | 19/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 18/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 17/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 16/20 | 0.40 |
| ▸ | CCNB3 | Q8WWL7 | 16/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.40 |
| ▸ | CDK7 | P50613 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | CCNH | P51946 | 1/20 | 0.40 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613094 | 0.97 | CDK2 (0.38) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL25613088 | 0.88 | GRM4 (0.40) | CDK2CDK1CCNB1CCNA2CCNA1 | |
| SCHEMBL25613106 | 0.84 | FEN1 (0.33) | CDK2CDK1CCNB1CDK5CCNT1 | |
| SCHEMBL25613097 | 0.84 | CHRNB4 (0.39) | — | |
| SCHEMBL25613093 | 0.83 | CHRNA3 (0.42) | — | |
| SCHEMBL25613105 | 0.83 | JAK2 (0.35) | CDK2CDK1CCNB1CDK5CCNT1 | |
| SCHEMBL25613114 | 0.82 | CHRNB4 (0.46) | — | |
| SCHEMBL25613103 | 0.81 | CHRNA3 (0.42) | CDK5 | |
| SCHEMBL25613086 | 0.81 | JAK3 (0.46) | CDK2CDK1 | |
| SCHEMBL25613037 | 0.80 | FEN1 (0.39) | CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | CDK2 51/4885CDK1 514/4885CCNB1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.